Chong Kun Dang Pharmaceutical Corp.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Trials
290
Trial Phases
5 Phases
Drug Approvals
2
Drug Approvals
Ceftizoxime Sodium for Injection
- Product Name
- 注射用头孢唑肟钠
- Approval Number
- 国药准字HJ20160453
- Approval Date
- Oct 13, 2021
Ceftizoxime Sodium for Injection
- Product Name
- 注射用头孢唑肟钠
- Approval Number
- 国药准字HJ20160452
- Approval Date
- Oct 13, 2021
Clinical Trials
Distribution across different clinical trial phases (284 trials with phase data)• Click on a phase to view related trials
A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT06979973
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Retrospective Observational Study on GERD Management in General Hospitals in Korea
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 13750
- Registration Number
- NCT06974903
- Locations
- 🇰🇷
Hanyang University Hospital, Seoul, Seongdong-gu, Korea, Republic of
Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981
- Conditions
- Knee Osteoarthritis
- Interventions
- Device: CKD-981(1)Device: CKD-981(2)Device: Sham deviceDrug: Placebo DrugDrug: Reference Drug
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT06954766
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Korea, Republic of
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
- Conditions
- Heart Transplant
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 140
- Registration Number
- NCT06942156
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: CKD-843 dose#1Drug: CKD-843 dose#2Drug: Placebo of CKD-843 doseDrug: Placebo of Dutasteride Capsule
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 288
- Registration Number
- NCT06916793
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 58
- Next
News
Diabetes Pipeline Shows Robust Growth with 200+ Companies Developing Novel Therapies
DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape.
Androgenetic Alopecia Pipeline Shows Promise with Over 100 Therapies in Development
DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages.
Novartis Secures $1.3 Billion Deal with Chong Kun Dang for HDAC6 Inhibitor Targeting CMT Disease
Novartis has signed a $1.3 billion licensing agreement with Korean biotech Chong Kun Dang Pharmaceutical for CKD-510, an HDAC6 inhibitor with FDA orphan drug designation for Charcot-Marie-Tooth disease.